{"product_id":"imtx-ansoff-analysis","title":"(IMTX) Immatics N.V. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the Full Ansoff Matrix for Deeper Strategic Insight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Immatics N.V. Ansoff Matrix Analysis gives a concise, company-specific view of growth options across market penetration, market development, product development, and diversification to support strategy, investment, or planning—this page includes a real preview\/sample of the analysis so you can judge format and depth before buying. Purchase the full version to receive the complete, ready-to-use Ansoff Matrix report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase I Progression of IMA201 in Solid Tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIMA201 is in Phase I and targets melanoma-associated antigens 4 or 8 in solid tumor patients, so Immatics N.V. is deepening its existing ACTengine base in U.S. oncology. This is a clear market penetration move: one current program, one current market, more attention in the same clinical niche. In 2025, Immatics held cash and cash equivalents of about $277 million, which supports continued clinical push without shifting away from its core platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase I Expansion of IMA202 Across Solid Tumor Types\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIMA202 expands Immatics' reach within the same solid-tumor market by extending one platform into at least 2 new indications, squamous non-small cell lung carcinoma and hepatocellular carcinoma, after melanoma-associated antigen 1 is already validated in solid tumors. That broader use can lift patient coverage without changing the core asset, which is classic market penetration. Immatics reported cash, cash equivalents, and marketable securities of $353.9 million at year-end 2025, supporting this multi-indication push.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePhase I Focus on Recurrent and Treatment-Resistant Solid Tumors\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIMA203 targets PRAME in adult patients with recurrent or treatment-resistant solid tumors, keeping Immatics in the same oncology market while narrowing to a high-need subgroup. Solid tumors make up about 90% of adult cancers, so the addressable base stays large even in niche use. This is a clear penetration play: the product and market are already in scope, but the unmet-need segment is tougher and more valuable.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMD Anderson Collaboration for ACTengine Clinical Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmatics’ collaboration with MD Anderson Cancer Center deepens access to a top U.S. cancer site that treats 80,000+ patients a year. For ACTengine, this can lift referral flow, investigator support, and trial visibility in the same T-cell and TCR therapy market, so it fits market penetration rather than expansion into a new field.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExisting market, deeper presence\u003c\/li\u003e\n\u003cli\u003eMD Anderson adds trial credibility\u003c\/li\u003e\n\u003cli\u003eSupports referral and investigator reach\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePharma Partnership Support for Current TCR Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmatics' market penetration strategy is reinforced by two external pharma alliances with GlaxoSmithKline Intellectual Property Development Limited and Celgene Switzerland LLC, both aimed at novel adoptive cell therapies. These deals validate the ACTengine platform and help keep development inside the same oncology market, where Immatics is already active. That supports share gains in current TCR programs rather than pushing into a new market. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTwo major pharma alliances\u003c\/li\u003e\n\u003cli\u003eExternal validation for ACTengine\u003c\/li\u003e\n\u003cli\u003eFocus stays on oncology\u003c\/li\u003e\n\u003cli\u003eStrengthens current market share\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmatics Expands Deep in TCR Oncology with $353.9M in Cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmatics N.V. is using market penetration by pushing ACTengine deeper into the same solid-tumor and TCR oncology space with IMA201, IMA202, and IMA203. The 2025 cash position of $353.9 million gave it room to keep expanding within current programs and sites without changing the core market. MD Anderson and pharma alliances with GlaxoSmithKline and Celgene also support stronger share in the same field.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eKey 2025 data\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and marketable securities\u003c\/td\u003e\n\u003ctd\u003e$353.9 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMD Anderson patient base\u003c\/td\u003e\n\u003ctd\u003e80,000+ per year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSolid tumors share of adult cancers\u003c\/td\u003e\n\u003ctd\u003eAbout 90%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eMaps Immatics N.V.’s growth options across existing and new products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise Immatics N.V. Ansoff Matrix view to quickly align growth strategy across products and markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a compact, verifiable source list that links each Ansoff growth path for Immatics N.V. to traceable primary and secondary references.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIMA202 Use in Multiple Solid Tumor Indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIMA202 fits market development because Immatics N.V. is taking the same asset into new solid-tumor segments, including squamous non-small cell lung carcinoma and hepatocellular carcinoma. That matters because NSCLC caused about 2.5 million new cases worldwide in 2022, while liver cancer cases were about 866,000. One drug, more patient pools, bigger addressable market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIMA203 Reach Into Broader Adult Solid Tumor Segments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIMA203 targets adult patients with recurrent or treatment-resistant solid tumors, so Immatics can reuse one program across multiple cancers instead of one tumor type. That is market development because it expands reach into broader clinical segments, especially where unmet need is highest and response rates are often below 20% in late-line solid tumors. The wider adult solid tumor setting also enlarges the addressable use case for PRAME-positive disease.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIMA204 Entry Into Tumor Stroma Targeting\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIMA204 is in preclinical development and targets tumor stroma cells, so Immatics is pushing its ACTengine TCR platform into a new solid-tumor niche. The platform stays the same, but the biological target changes, which fits market development: same engine, new disease segment. This matters because solid tumors still make up about 90% of adult cancers, and IMA204 broadens Immatics beyond its current T-cell focus.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMD Anderson Network for Wider Clinical Access\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eMD Anderson widens Immatics N.V.’s clinical reach by testing multiple T-cell and TCR-based adoptive cell therapies in a top cancer-center setting. That matters because MD Anderson treats a very large and diverse oncology population, so Immatics can reach more referral paths and patient types without changing the core programs. This is market development: the same pipeline is moved into a broader market venue.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpands trial access\u003c\/li\u003e\n\u003cli\u003eBroadens referral channels\u003c\/li\u003e\n\u003cli\u003eReaches new patient groups\u003c\/li\u003e\n\u003cli\u003eUses existing programs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGenmab Collaboration for Diverse Cancer Indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmatics and Genmab are applying Immatics’ T-cell engager science beyond ACTengine into broader oncology markets, which is classic market development: same know-how, new disease settings. Genmab’s bispecific platform helps widen the target pool across multiple cancer indications, not just one tumor type. In a global oncology market that topped $200 billion in 2025, that kind of indication expansion can create a much larger commercial path.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses existing T-cell biology\u003c\/li\u003e\n\u003cli\u003eExpands into new cancer indications\u003c\/li\u003e\n\u003cli\u003eBroadens reach beyond ACTengine\u003c\/li\u003e\n\u003cli\u003eTargets a \u0026gt;$200B oncology market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmatics Expands Into New Solid-Tumor Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmatics N.V. is using the same TCR and T-cell platform to enter new solid-tumor segments, so Market Development fits. IMA202 extends into squamous NSCLC and HCC, while IMA203 widens use across recurrent solid tumors. MD Anderson and the Genmab deal also expand access and indication reach.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003eMarket effect\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIMA202\u003c\/td\u003e\n\u003ctd\u003eNew tumor types\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIMA203\u003c\/td\u003e\n\u003ctd\u003eBroader adult use\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMD Anderson\/Genmab\u003c\/td\u003e\n\u003ctd\u003eWider reach\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eImmatics N.V. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIMA204 Tumor Stroma Cell Program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIMA204 is a preclinical tumor stroma cell program, so it adds a new target class to Immatics N.V.’s solid-tumor pipeline and extends the company beyond its Phase I ACTengine candidates. In Ansoff Matrix terms, this is product development: a new product for an existing oncology market. Immatics is broadening from T-cell therapies into stromal targeting in 2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIMA401 Cancer Testis Antigen TCR Bispecific\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIMA401 expands Immatics N.V.’s preclinical TCR Bispecifics line with a new format for the same solid tumor market. It targets cancer testis antigens, so it adds depth beyond the company’s ACTengine cell therapies. That makes it clear product development: a new product line aimed at the same cancer space.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIMA402 Solid Tumor TCR Bispecific Program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIMA402 is a preclinical TCR bispecific for solid tumors, so it fits product development: Immatics N.V. is adding a new product to an existing oncology market. It broadens the bispecific pipeline to 2 programs, alongside IMA401, and strengthens the company’s focus on solid tumor therapies. The step matters because it aims to expand one treatment area with a second differentiated asset before clinical proof-of-concept.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIMA301 Allogeneic Cellular Therapy Candidate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIMA301 is an allogeneic cellular therapy candidate, so it adds a new cell-therapy format next to Immatics N.V.'s autologous ACTengine approach. That makes it a clear product development move in Ansoff terms: same cancer-immunotherapy market, new product type. It broadens the pipeline beyond ACTengine and aims at off-the-shelf use, which can matter if manufacturing speed and scale improve.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew product, same market\u003c\/li\u003e\n\u003cli\u003eAllogeneic, not autologous\u003c\/li\u003e\n\u003cli\u003eExpands cancer immunotherapy\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIMA101 Cancer Treatment Program\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIMA101 broadens Immatics N.V.’s oncology pipeline by adding another cancer treatment candidate to its existing market. That makes this a product development move, because it expands the menu of assets inside the same cancer therapy space, alongside ACTengine and TCR Bispecifics.\u003c\/p\u003e\n\u003cp\u003eFor 2025, the key value is pipeline depth: more shots on goal in a market where oncology remains the core focus and one approved asset still has to clear clinical risk. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore candidates, same cancer market\u003c\/li\u003e\n\u003cli\u003eAdds breadth to the pipeline\u003c\/li\u003e\n\u003cli\u003eFits product development in Ansoff\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmatics Expands Solid-Tumor Pipeline with 5 New Oncology Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmatics N.V.’s product development in 2025 is about adding new oncology assets for the same solid-tumor market: 5 pipeline candidates now span ACTengine, TCR bispecifics, stromal targeting, and allogeneic therapy. That is classic Ansoff product development: new products, same cancer space.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePipeline breadth\u003c\/td\u003e\n\u003ctd\u003e5 candidates\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMain market\u003c\/td\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMove\u003c\/td\u003e\n\u003ctd\u003eNew products, same market\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenmab-Linked T-Cell Engaging Bispecific Immunotherapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Genmab collaboration moves Immatics N.V. from ACTengine cell therapies into T-cell engaging bispecific immunotherapies, so it adds a new product family and a new oncology modality market. That is classic diversification: new products for new cancer segments, not just more of the same pipeline. The move matters because bispecifics are a distinct drug class now advancing across solid tumors and hematologic cancers.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAllogeneic Cell Therapy via IMA301\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIMA301 is Immatics N.V.’s allogeneic cell therapy candidate, so it moves beyond the company’s current autologous TCR-based ACT portfolio. This is true diversification in the Ansoff Matrix: a new product type in a new market segment, with a different development path and manufacturing model. Unlike patient-specific autologous therapy, allogeneic therapy can be made for broader use, which changes the commercial playbook.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCancer Testis Antigen Bispecifics with IMA401\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIMA401 is a cancer testis antigen bispecific built on Immatics' TCR Bispecific platform, so it moves the company into a new solid tumor immunotherapy class. Unlike ACTengine cell therapies, it is a different product with a different market path, which fits Ansoff diversification: new product, new market. In 2025, this kind of shift matters as bispecifics keep drawing capital and trials across oncology.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTumor Microenvironment Targeting with IMA204\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIMA204 moves Immatics N.V. into diversification because it targets tumor stroma cells, not the tumor-cell programs already in clinic. That opens a new biological target environment and a different therapeutic market, so the company is adding more than one product line. It also broadens risk across tumor biology, which is the core Ansoff signal here.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTargets stroma, not tumor cells\u003c\/li\u003e\n\u003cli\u003eOpens a new market segment\u003c\/li\u003e\n\u003cli\u003eExpands beyond existing programs\u003c\/li\u003e\n\u003cli\u003eFits Ansoff diversification\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMulti-Partner Oncology Development Model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmatics N.V. uses a multi-partner oncology model with GSK, MD Anderson, Celgene Switzerland, and Genmab, so development is spread across 4 collaboration lanes. That widens exposure across cancer targets and modalities, and it reduces reliance on one product or one partner. In Ansoff terms, this is clear diversification: new products, new programs, and adjacent channels at the same time.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\u003cli\u003e\u003c\/ul\u003e\n\u003cli\u003e4 partner ecosystem lowers single-partner risk\u003c\/li\u003e\n\u003cli\u003eMultiple indications widen pipeline reach\u003c\/li\u003e\n\u003cli\u003eParallel programs support faster market entry\u003c\/li\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmatics Bets Big on New Oncology Modalities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eDiversification in Immatics N.V.’s Ansoff Matrix is strongest where the Company moves into new oncology modalities and targets, not just new indications. The Genmab deal, IMA301, IMA401, and IMA204 each expand beyond the core ACTengine base into distinct product classes and market paths.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMove\u003c\/th\u003e\n\u003cth\u003e2025\/2026 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenmab collaboration\u003c\/td\u003e\n\u003ctd\u003e1 new modality lane\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIMA301\u003c\/td\u003e\n\u003ctd\u003eAllogeneic therapy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIMA401\u003c\/td\u003e\n\u003ctd\u003eBispecific class\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIMA204\u003c\/td\u003e\n\u003ctd\u003eStroma target\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234542461193,"sku":"imtx-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/imtx-ansoff-matrix.webp?v=1785721864","url":"https:\/\/dcfanalyst.com\/products\/imtx-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}